HuMax-CD20 in Active Rheumatoid Arthritis, Phase I/II
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is primarily to investigate the safety profile of HuMax-CD20 in
patients with active RA. Furthermore, the trial is designed to identify the dose levels to be
used in future trials (based on evaluations of safety, pharmacokinetics and ACR and DAS
responses).